Develops neuro-immunotherapy treatments that combine neurobiology and immunology to address neurological and immune disorders. Utilizing proprietary biologics and small molecule therapeutics, these non-invasive therapies target the underlying mechanisms of these conditions, offering potential improvements in patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Neurological and immune disorders often lack effective treatments due to the complex interplay between the nervous and immune systems. Current therapies may not target the underlying mechanisms of these conditions, leading to limited improvements in patient outcomes. The invasive nature of some treatments also presents challenges for patients.
Solution
Interon Laboratories is developing neuro-immunotherapies, a novel approach that integrates neurobiology and immunology to treat neurological and immune disorders. Their non-invasive therapies utilize proprietary biologics and small molecule therapeutics designed to target the root causes of these conditions. By addressing the interaction between the nervous and immune systems, Interon aims to offer improved and more effective treatment options. The company's technology is based on discoveries made at MIT and Harvard Medical School.
Target Audience
The primary target audience includes individuals suffering from neurological and immune disorders, as well as healthcare providers seeking innovative treatment options.
Features
- Development of biologics-based therapies for neurological disorders.
- Development of small molecule therapeutics for neurological disorders.
- Non-invasive therapeutic approaches.
- Targets the underlying mechanisms of neuro-immune interaction.